Article Details
Retrieved on: 2022-10-11 18:00:59
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer has completed its $5.4 billion acquisition of GBT, bringing it Oxbryta, a sickle cell disease-modifying therapy, and inclacumab.
Article found on: sicklecellanemianews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here